Features of ovarian cancer in Lynch syndrome (Review)

Nakamura,Kanako; Banno,Kouji; Yanokura,Megumi; Iida,Miho; Adachi,Masataka; Masuda,Kenta; Ueki,Arisa; Kobayashi,Yusuke; Nomura,Hiroyuki; Hirasawa,Akira; Tominaga,Eiichiro; Aoki,Daisuke

doi:10.3892/mco.2014.397

Features of ovarian cancer in Lynch syndrome (Review)

Authors:
- Kanako Nakamura
- Kouji Banno
- Megumi Yanokura
- Miho Iida
- Masataka Adachi
- Kenta Masuda
- Arisa Ueki
- Yusuke Kobayashi
- Hiroyuki Nomura
- Akira Hirasawa
- Eiichiro Tominaga
- Daisuke Aoki
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160‑8582, Japan
Published online on: August 20, 2014 https://doi.org/10.3892/mco.2014.397
Pages: 909-916

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9‑2.7%. Lynch syndrome accounts for 10‑15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65‑75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non‑serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3‑kinase/mammalian target of the rapamycin pathway and anti‑epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.

View Figures

View References

1	Crispens MA: Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg. 25:97–102. 2012. View Article : Google Scholar : PubMed/NCBI
2	Neesham D: Ovarian cancer screening. Aust Fam Physician. 36:126–128. 2007.
3	Lu KH: Clinical relevance of hereditary endometrial cancer. Hereditary gynecologic cancer: risk, prevention, and management. 1st edition. Informa Healthcare; New York, NY: pp. 15–28. 2008
4	Bewtra C, Watson P, Conway T, Read-Hippee C and Lynch HT: Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 11:180–187. 1992. View Article : Google Scholar : PubMed/NCBI
5	Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 116:1453–1456. 1999. View Article : Google Scholar
6	Jascur T and Boland CR: Structure and function of the components of the human DNA mismatch repair system. lnt J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI
7	Harfe BD and Jinks-Robertson S: DNA mismatch repair and genetic instability. Annu Rev Genet. 34:359–399. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kuiper RP, Vissers LE, Venkatachalam R, et al: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat. 32:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
9	Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar
10	Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer. 81:214–218. 1999. View Article : Google Scholar : PubMed/NCBI
11	Watson P, Vasen HF, Menklin JP, et al: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 123:444–449. 2008. View Article : Google Scholar : PubMed/NCBI
12	Engel C, Loeffler M, Steinke V, et al: Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 30:4409–4415. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ketabi Z, Bartuma K, Bernstein I, et al: Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 121:462–465. 2011. View Article : Google Scholar : PubMed/NCBI
14	Watson P, Bützow R, Lynch HT, et al; International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 82:223–228. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lu K: Gynecological malignancy as a ‘sentinel cancer’ for women with HNPCC. Gynecol Oncol. 92:4212004.
16	Vasen HF, Stormorken A, Menko FH, et al: MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 19:4074–4080. 2001.PubMed/NCBI
17	Cederquist K, Emanuelsson M, Wiklund F, Golovleva I, Palmqvist R and Grönberg H: Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet. 68:533–541. 2005. View Article : Google Scholar : PubMed/NCBI
18	Sood AK, Holmes R, Hendrix MJ and Buller RE: Application of the National Cancer Institute International criteria for determination of microsatellite instability in ovarian cancer. Cancer Res. 61:4371–4374. 2001.PubMed/NCBI
19	Gras E, Catasus L, Argüelles R, et al: Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer. 92:2829–2836. 2001. View Article : Google Scholar : PubMed/NCBI
20	Cai KQ, Albarracin C, Rosen D, et al: Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 35:552–559. 2004. View Article : Google Scholar : PubMed/NCBI
21	Rosen DG, Cai KQ, Luthra R and Liu J: Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 19:1414–1420. 2006.PubMed/NCBI
22	Malander S, Rambech E, Kristoffersson U, et al: The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 101:238–243. 2006. View Article : Google Scholar : PubMed/NCBI
23	Domanska K, Malander S, Måsbäck A and Nilbert M: Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer. 17:789–793. 2007. View Article : Google Scholar : PubMed/NCBI
24	Shaw PA, McLaughlin JR, Zweemer RP, et al: Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 21:407–411. 2002. View Article : Google Scholar : PubMed/NCBI
25	Piek JM, Torrenga B, Hermsen B, et al: Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2:73–78. 2003. View Article : Google Scholar : PubMed/NCBI
26	Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al: Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer. 4:301–305. 2005. View Article : Google Scholar : PubMed/NCBI
27	Watson P and Lynch HT: Cancer risk in mismatch repair gene mutation carriers. Fam Cancer. 1:57–60. 2001. View Article : Google Scholar : PubMed/NCBI
28	Grindedal EM, Renkonen-Sinisao L, Vasen H, et al: Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet. 47:99–102. 2010. View Article : Google Scholar : PubMed/NCBI
29	Aebi S, Kurdi-Haidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:3087–3090. 1996.PubMed/NCBI
30	Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLHl gene promoter. Cancer Res. 60:6039–6044. 2000.
31	Helleman J, van Staveren IL, Dinjens WN, et al: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 6:2012006. View Article : Google Scholar : PubMed/NCBI
32	Lindor NM, Petersen GM, Hadley DW, et al: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 296:1507–1517. 2006. View Article : Google Scholar : PubMed/NCBI
33	Brown GJ, St John DJ, Macrae FA and Aittomäki K: Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol. 80:346–349. 2001. View Article : Google Scholar : PubMed/NCBI
34	Zurawski VR Jr, Orjaseter H, Anderson A and Jellum E: Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 42:677–680. 1988. View Article : Google Scholar : PubMed/NCBI
35	Zurawski VR Jr, Sjovall K, Schoenfeld DA, et al: Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 36:299–305. 1990. View Article : Google Scholar
36	Skates SJ, Xu FJ, Yu YH, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 76(10 Suppl): 2004–2010. 1995. View Article : Google Scholar : PubMed/NCBI
37	Buys SS, Partridge E, Greene MH, et al; PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 193:1630–1639. 2005. View Article : Google Scholar : PubMed/NCBI
38	Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 306:1030–1034. 1993. View Article : Google Scholar : PubMed/NCBI
39	Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI
40	Jacobs IJ, Mackay J, Menon U, Skates SJ, Rosenthal AN and Fraser L: Familial ovarian screening - effective or ineffective? Br J Cancer. 95(1124): 1126–1127. 2006. View Article : Google Scholar : PubMed/NCBI
41	Partridge E, Kreimer AR, Buys S, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian Screening Trial: Results from 4 years of annual screening in a randomized trial. Gynecol Oncol. 104(Suppl 3): abstr 10. S2–S35. 2007.
42	Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium JAMA. 227:997–1003. 1997.PubMed/NCBI
43	Armstrong K, Micco E, Carney A, Stopfer J and Putt M: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 293:1729–1736. 2005. View Article : Google Scholar : PubMed/NCBI
44	Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 31:49–57. 2013. View Article : Google Scholar
45	Burn J, Gerdes AM, Macrae F, et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar
46	No authors listed. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and steroid Hormone Study. JAMA. 249:1600–1604. 1983. View Article : Google Scholar : PubMed/NCBI
47	No authors listed. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study for the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 316:650–655. 1987. View Article : Google Scholar : PubMed/NCBI
48	Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 339:424–428. 1998. View Article : Google Scholar : PubMed/NCBI
49	Tavani A, Ricci E, La Vecchia C, et al: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
50	Whittemore AS, Balise RR, Pharoah PD, et al: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 91:1911–1915. 2004. View Article : Google Scholar : PubMed/NCBI
51	McLaughlin JR, Risch HA, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 8:26–34. 2007. View Article : Google Scholar : PubMed/NCBI
52	Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 277:915–919. 1997. View Article : Google Scholar : PubMed/NCBI
53	Bertagnolli MM: Surgical prevention of cancer. J Clin Oncol. 23:324–332. 2005. View Article : Google Scholar
54	Lynch HT, Watson P, Shaw TG, et al: Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer. 86(11 Suppl): 2457–2463. 1999. View Article : Google Scholar
55	Lu KH, Dinh M, Kolhmann W, et al: Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 105:569–574. 2005.
56	Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 354:261–269. 2006. View Article : Google Scholar : PubMed/NCBI
57	Banno K, Kisu I, Yanokura M, et al: Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome (Review). Int J Oncol. 41:793–797. 2012.PubMed/NCBI
58	Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG and Vasen HF: Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 102:198–200. 2002. View Article : Google Scholar : PubMed/NCBI
59	Chen LM, Yang KY, Little SE, Cheung MK and Caughey AB: Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol. 110:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
60	Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:1609–1615. 2002. View Article : Google Scholar : PubMed/NCBI
61	Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1616–1622. 2002. View Article : Google Scholar : PubMed/NCBI
62	Schmeler KM, Daniels MS, Soliman PT, et al: Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol. 115:432–434. 2010. View Article : Google Scholar : PubMed/NCBI
63	Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF and Bardawil WA: Role of heredity in multiple primary cancer. Cancer. 40(4 Suppl): 1849–1854. 1977. View Article : Google Scholar : PubMed/NCBI
64	Parker WH, Broder MS, Liu Z, et al: Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 106:219–226. 2005. View Article : Google Scholar : PubMed/NCBI
65	Niskakoski A, Kaur S, Renkonen-Sinisalo L, et al: Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer. 133:2596–2608. 2013.PubMed/NCBI
66	Oda K: Targeting Ras-PI3K/mTOR pathway and predictive biomarkers in endometrial cancer. Gan To Kagaku Ryoho. 38:1084–1087. 2011.(In Japanese).
67	Costa-Guda J, Soong CP, Parekh VI, Agarwal SK and Arnold A: Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 4:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
68	Jürgens B, Schmitz-Dräger BJ and Schulz WA: Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res. 56:5698–5703. 1996.PubMed/NCBI
69	Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 41:664–668. 2004. View Article : Google Scholar : PubMed/NCBI
70	Woloszynska-Read A, Zhang W, Yu J, et al: Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 17:2170–2180. 2011. View Article : Google Scholar